X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Under the agreement, SciClone will pursue the development and registration of Orserdu (elacestrant), a once-daily oral endocrine monotherapy, for the treatment of postmenopausal women or adult men, in China and commercialize Orserdu upon its regulatory approval in China.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciClone Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 07, 2023
Details:
Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Organisation for Research and Treatment of Cancer
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
Under the agreement, DRI Healthcare gains a portion of Radius’s royalty and commercial milestone stream in Orserdu (elacestrant), a selective estrogen receptor degrader and the first and only treatment approved for ER+/HER2-, ESR1- mutated advanced or metastatic breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: DRI Healthcare
Deal Size: $140.0 million Upfront Cash: $130.0 million
Deal Type: Agreement August 14, 2023
Details:
Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
Under the agreement, Eisai transfers all future economic rights for elacestrant, a selective estrogen receptor degrader, approved for the treatment for breast cancer in the United States, to DRI Healthcare Trust.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Elacestrant-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: DRI Healthcare
Deal Size: Undisclosed Upfront Cash: $85.0 million
Deal Type: Agreement June 29, 2023
Details:
Orserdu (elacestrant) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). It inhibits 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
Orserdu (elacestrant) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). It inhibits 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
RAD1901 (elacestrant) is an investigational selective estrogen receptor degrader (SERD). Preclinical studies indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: RAD1901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Elacestrant (RAD1901), if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: RAD1901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Radius Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2022
Details:
Submission supported by results from pivotal Phase 3 EMERALD study of RAD1901 (elacestrant) showing statistically significant efficacy over current standard-of-care (SOC) medications for both overall study population and patients whose tumors harbor an ESR1 mutation.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: RAD1901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
RAD1901 (elacestrant) is the first and currently only investigational oral SERD to show positive topline results in a pivotal trial for the treatment of ER+/HER2- advanced or metastatic breast cancer in postmenopausal women, and men.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: RAD1901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
Elacestrant (RAD1901), is an investigational selective estrogen receptor degrader (SERD), out-licensed to Menarini Group, which is being evaluated for potential use as a once daily oral treatment in patients with ER+/ HER2- advanced breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: RAD1901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Radius Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
RAD1901 (elacestrant) is a selective estrogen receptor degrader (SERD), out-licensed to Menarini Group, which is being evaluated for potential use as a once daily oral treatment in patients with ER+/ HER2- advanced breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: RAD1901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Details:
RAD1901 (Elacestrant) is a SERD, being evaluated for potential use once daily oral treatment in patients with ER+/ HER2- advanced breast cancer, studies showed that it reduced risk of progression or death by 30%.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: RAD1901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2021
Details:
The trial results being statistically significant demonstrate a clinically meaningful improvement of PFS in the elacestrant group versus endocrine standard of care in patients previously treated with endocrine therapies and CDK 4/6 inhibitors.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: RAD1901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Radius Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2021
Details:
Elacestrant is an oral Selective Estrogen Receptor Degrader (SERD) that is being studied in postmenopausal women and men with ER+/HER2- advanced or metastatic breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: RAD1901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2020
Details:
Elacestrant is an oral SERD, a selective estrogen receptor degrader, currently being evaluated in the EMERALD Phase 3 study as hormonal treatment for postmenopausal women and men with advanced ER+/HER2- breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: RAD1901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: $350.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement July 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
